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Predictor	variables	 β	(SE)	 95%	CI	 P	 β	(SE)	 95%	CI	 p	
Categories	of	diabetes	and	multimorbidities	 	 	 	 	 	 	
			Diabetes	only	(reference)	 	 	 	 	 	 	
			Diabetes	plus	1	chronic	condition	 -0.31	(0.26)	 -0.84,	0.21	 0.240	 -0.27	(0.29)	 -0.83,	0.29	 0.345	
			Diabetes	plus	2	chronic	conditions	 -0.15	(0.27)	 -0.68,	0.38	 0.575	 -0.22	(0.29)	 -0.79,	0.35	 0.450	
			Diabetes	plus	3	chronic	conditions	 -0.00	(0.29)	 -0.58,	0.57	 0.996	 0.06	(0.32)	 -0.56,	0.68	 0.844	
			Diabetes	plus	≥4	chronic	conditions	 -0.20	(0.27)	 -0.73,	0.32	 0.460	 -0.20	(0.30)	 -0.78,	0.38	 0.504	
Categories	of	diabetes	and	concordant	conditions	 	 	 	 	 	 	
			Diabetes	only	(reference)	 	 	 	 	 	 	
			Diabetes	plus	1	concordant	condition	 -0.18	(0.18)	 -0.52,	0.17	 0.317	 -0.10	(0.19)	 -0.47,	0.26	 0.578	
			Diabetes	plus	2	concordant	conditions	 -0.04	(0.22)	 -0.46,	0.39	 0.865	 -0.04	(0.24)	 -0.50,	0.43	 0.880	
			Diabetes	plus	3	concordant	conditions	 0.04	(0.29)	 -0.54,	0.60	 0.915	 0.21(0.31)	 -0.39,	0.83	 0.488	
			Diabetes	plus	≥4	concordant	conditions	 -0.06	(0.39)	 -0.83,	0.71	 0.884	 -0.01	(0.42)	 -0.83,	0.80	 0.979	
Categories	of	diabetes	and	discordant	conditions	 	 	 	 	 	 	
			Diabetes	only	(reference)	 	 	 	 	 	 	
			Diabetes	plus	1	discordant	condition	 0.14	(0.18)	 -0.21,	0.50	 0.433	 0.13	(0.19)	 -0.26,	0.51	 0.517	
			Diabetes	plus	2	discordant	conditions	 0.26	(0.20)	 -0.13,	0.66	 0.183	 0.21	(0.21)	 -0.20,	0.61	 0.320	
			Diabetes	plus	3	discordant	conditions	 -0.14	(0.27)	 -0.68,	0.40	 0.611	 -0.20	(0.29)	 -0.78,	0.37	 0.488	










Predictor	variables	 β	(SE)	 95%	CI	 P	 β	(SE)	 95%	CI	 p	
Categories	of	diabetes	and	multimorbidities	 	 	 	 	 	 	
			Diabetes	only	(reference)	 	 	 	 	 	 	
			Diabetes	plus	1	chronic	condition	 2.52	(1.76)	 -0.94,	5.97	 0.154	 0.09	(1.75)	 -3.34,	3.52	 0.959	
			Diabetes	plus	2	chronic	conditions	 4.44	(1.78)	 0.96,	7.93	 0.012	 1.70	(1.78)	 -1.78,	5.18	 0.338	
			Diabetes	plus	3	chronic	conditions	 1.97	(1.94)	 -0.83,	5.78	 0.309	 -1.20	(1.93)	 -4.99,	2.58	 0.533	
			Diabetes	plus	≥4	chronic	conditions	 3.93	(1.81)	 0.39,	7.48	 0.029	 -0.45	(1.87)	 -4.11,	3.21	 0.808	
Categories	of	diabetes	and	concordant	conditions	 	 	 	 	 	 	
			Diabetes	only	(reference)	 	 	 	 	 	 	
			Diabetes	plus	1	concordant	condition	 2.92	(1.14)	 0.70,	5.15	 0.010	 1.34	(1.11)	 -0.85,	5.53	 0.230	
			Diabetes	plus	2	concordant	conditions	 4.84	(1.39)	 2.11,	7.56	 0.001	 2.57	(1.42)	 -0.20,	5.36	 0.070	
			Diabetes	plus	3	concordant	conditions	 0.49	(1.88)	 -3.19,	4.17	 0.794	 -1.43	(1.86)	 -5.08,	2.22	 0.442	
			Diabetes	plus	≥4	concordant	conditions	 5.53	(2.57)	 0.50,	10.55	 0.031	 -0.98	(2.65)	 -6.18,	4.21	 0.711	
Categories	of	diabetes	and	discordant	conditions	 	 	 	 	 	 	
			Diabetes	only	(reference)	 	 	 	 	 	 	
			Diabetes	plus	1	discordant	condition	 -0.34	(1.23)	 -2.75,	2.07	 0.782	 -1.33	(1.17)	 -3.63,	0.97	 0.258	
			Diabetes	plus	2	discordant	conditions	 -0.61	(1.38)	 -3.31,	2.09	 0.657	 -1.84	(1.29)	 -4.37,	0.68	 0.153	
			Diabetes	plus	3	discordant	conditions	 0.39	(1.83)	 -3.20,	3.98	 0.832	 -1.10	(1.77)	 -4.57,	2.37	 0.536	










Predictor	variables	 β	(SE)	 95%	CI	 P	 β	(SE)	 95%	CI	 p	
Categories	of	diabetes	and	multimorbidities	 	 	 	 	 	 	
			Diabetes	only	(reference)	 	 	 	 	 	 	
			Diabetes	plus	1	chronic	condition	 3.09	(5.58)	 -7.84,	14.04	 0.579	 0.92	(5.96)	 -10.77,	12.61	 0.877	
			Diabetes	plus	2	chronic	conditions	 -5.84	(5.63)	 -16.85,	5.17	 0.299	 -6.75	(6.04)	 -18.58,	5.09	 0.264	
			Diabetes	plus	3	chronic	conditions	 -2.46	(6.13)	 -14.47,	9.55	 0.688	 -6.51	(6.56)	 -19.37,	6.36	 0.322	
			Diabetes	plus	≥4	chronic	conditions	 -2.93	(5.66)	 -14.01,	8.16	 0.605	 -4.96	(6.28)	 -17.26,	7.34	 0.430	
Categories	of	diabetes	and	concordant	conditions	 	 	 	 	 	 	
			Diabetes	only	(reference)	 	 	 	 	 	 	
			Diabetes	plus	1	concordant	condition	 1.71	(3.69)	 -5.51,	8.94	 0.642	 0.77	(3.84)	 -6.76,8.30	 0.841	
			Diabetes	plus	2	concordant	conditions	 -6.02	(4.49)	 -14.82,	2.78	 0.180	 -7.95	(4.85)	 -17.47,1.56	 0.101	
			Diabetes	plus	3	concordant	conditions	 -0.66	(6.09)	 -12.60,	11.28	 0.914	 -3.73	(6.43)	 -16.34,	8.86	 0.561	
			Diabetes	plus	≥4	concordant	conditions	 4.89	(8.24)	 -11.27,	21.04	 0.553	 2.64	(8.71)	 -14.43,	19.72	 0.762	
Categories	of	diabetes	and	discordant	conditions	 	 	 	 	 	 	
			Diabetes	only	(reference)	 	 	 	 	 	 	
			Diabetes	plus	1	discordant	condition	 -1.92	(3.81)	 -9.39,	5.54	 0.615	 -2.30	(3.98)	 -10.11,	5.50	 0.563	
			Diabetes	plus	2	discordant	conditions	 -8.59	(4.19)	 -16.81,	-0.37	 0.040	 -7.87	(4.24)	 -16.18,	0.43	 0.063	
			Diabetes	plus	3	discordant	conditions	 5.85	(5.70)	 -5.33,	17.03	 0.305	 8.40	(5.98)	 -3.32,	20.11	 0.160	
			Diabetes	plus	≥4	discordant	conditions	 -8.65	(7.28)	 -22.92,	5.61	 0.234	 -9.52	(7.82)	 -24.86,	5.82	 0.224	
	
SE:	Standard	error	
Adjusting	for	age,	gender,	socioeconomic	status,	BMI,	smoking	status,	insulin	use,	and	number	of	non-insulin	hypoglycaemic	medication.	All	co-variates	
were	treated	as	fixed	effects	and	the	general	practice	as	a	random	effect	to	allow	for	the	correlation	of	TIR	within	each	practice.	
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4.	DISCUSSION	1	
In	this	study,	we	examined	associations	between	multimorbidity	and	measures	of	glycaemia	in	279	2	
people	with	T2D	in	Australian	general	practice	using	data	from	the	GP-OSMOTIC	trial	collected	at	the	3	
time	of	patient	enrolment.	The	majority	of	people	with	T2D	in	this	cohort	(89.2%)	were	living	with	4	
multimorbidity.	We	used	CGM	data	to	derive	GV	and	TIR	in	this	cohort.	Our	findings	suggest	that	5	
there	was	no	significant	relationship	between	multimorbidity	(total,	concordant	and	discordant)	and	6	
various	measures	of	glycaemia,	including	HbA1c,	GV	(using	CV),	and	TIR,	reflecting	glucose	control	7	
over	3-months	to	several	weeks	respectively.	8	
	9	
Uncertainty	exists	about	the	association	between	multimorbidity	and	HbA1c	in	people	with	T2D	(18).	10	
We	did	not	find	significant	relationships	between	multimorbidity	and	a	single	concurrent	measure	of	11	
HbA1c,	nor	CGM	related	measures	of	glycaemia	in	this	cohort.	Our	findings	may	be	linked	to	the	12	
higher	health	care	utilisation	(29)	and	better	quality	of	care	(30)	seen	in	people	with	other	LTCs.	13	
Higher	health	care	utilisation	may	result	in	more	opportunities	for	clinical	interventions	leading	to	14	
better	glycaemic	management.	We	did	not	explore	health	utilisation,	nor	did	we	evaluate	HbA1c	15	
measures	over	the	longer	term.	16	
	17	
Evidence	suggests	associations	between	higher	GV	and	micro-	and	macrovascular	complications	(13,	18	
14)	including	the	development	of	diabetes	peripheral	neuropathy	(31),	and	the	development	of	19	
cardiovascular	diseases	(32).	Lower	TIR	has	been	linked	to	the	development	of	diabetic	retinopathy	20	
and	diabetic	nephropathy	(15).	There	is	good	evidence	of	a	relationship	between	higher	GV,	lower	21	
TIR	and	complications	of	T2D,	yet	we	did	not	find	any	significant	associations	between	concordant	22	
LTCs	(which	include	some	important	complications	of	T2D),	GV	and	TIR.	23	
	24	
To	the	best	of	our	knowledge,	this	is	the	first	study	to	explore	the	effect	of	the	total	burden	of	25	
disease	reflected	in	multimorbidity	on	GV	and	TIR	in	people	with	T2D.	The	prevalence	of	26	
multimorbidity	and	individual	LTCs	in	this	study	align	with	the	prevalence	numbers	found	in	studies	27	
of	community	cohorts	of	people	with	T2D	in	the	UK	and	Taiwan	(4).	This	suggests	that	a	strength	of	28	
this	study	is	that	we	could	capture	multimorbidity	and	LTCs	similar	to	the	general	population	of	29	
people	with	T2D	despite	using	a	specialised	RCT	T2D	cohort	in	general	practice.	There	are	some	30	
limitations	to	note	for	our	study.	This	was	a	cross-sectional	analysis	of	a	relatively	small	sample	size	31	
using	baseline	data	from	the	GP-OSMOTIC	trial,	which	was	powered	to	detect	differences	in	HbA1c	32	
between	the	intervention	and	control	groups.	Therefore,	there	may	be	insufficient	statistical	power	33	
to	observe	differences	in	GV	and	TIR	across	different	multimorbidity	categories.	We	therefore	did	34	
13	
	
not	explore	the	effects	of	individual	LTCs	on	glycaemic	measures.	Information	on	LTCs	for	this	cohort	1	
was	only	collected	at	baseline	and	we	were	unable	to	model	for	changes	in	multimorbidity.	2	
Therefore,	a	limitation	of	our	study	is	that	we	were	unable	to	consider	the	temporality	and	duration	3	
of	the	conditions	in	addition	to	diabetes.		Another	limitation	is	that	the	study	only	included	people	4	
attending	general	practice.	It	is	possible	that	people	attending	general	practice,	as	opposed	to	those	5	
receiving	care	from	specialists,	may	have	a	lower	GV	as	we	observed	the	mean	(SD)	CV	was	30.0	6	
(8.3)%	which	was	below	the	consensus	cut-off	of	36%	defining	high	GV	(11).	As	a	result,	we	do	not	7	
know	if	our	results	apply	to	the	population	that	experience	higher	levels	of	GV.	Therefore,	those	8	
with	worse	GV,	who	may	be	seeing	specialists	and	attending	hospital	clinics	may	not	be	represented.	9	
However,	this	cohort	of	people	with	T2D	had	HbA1c	levels	significantly	above	the	recommended	10	
target.	Although	the	mean	CV	of	this	cohort	was	not	high	as	determined	by	the	consensus	cut-off,	11	
the	mean	(SD)	TIR	of	41.1	(25.6)%	was	relatively	low.	The	higher	levels	of	HbA1c	and	low	TIR	in	this	12	
cohort	may	be	linked	to	why	we	did	not	observe	significant	differences	in	our	outcomes	between	the	13	
different	categories	of	multimorbidity.	Detecting	a	difference	in	our	outcomes	might	have	been	14	
more	likely	in	a	cohort	with	a	greater	spread	of	HbA1c,	CV	and	TIR.	15	
	16	
There	is	an	association	between	multimorbidity	and	increased	mortality	in	people	with	T2D	(4,	18).	17	
We	explored	multimorbidity’s	effects	on	measures	of	blood	glucose	as	a	way	to	help	us	understand	18	
the	underlying	mechanisms	to	the	increased	mortality	seen	in	those	with	LTCs.	Our	findings	suggest	19	
that	future	studies	should	explore	factors	other	than	glycaemic	measures,	that	could	contribute	to	20	
the	increased	mortality	that	has	been	observed	elsewhere.	Future	research	involving	larger	patient	21	
populations	to	examine	how	clinicians	and	people	with	T2D	utilise	CGM	and	interpret	CGM	outputs	22	
to	approach	glycaemic	targets	and	make	treatment	decisions	in	the	context	of	multimorbidity	are	23	
warranted.	24	
	25	
CONCLUSION	26	
In	279	well	characterised	people	with	T2D	in	Australian	general	practice,	we	found	no	significant	27	
associations	between	multimorbidity	counts,	HbA1c,	GV	and	TIR.	This	study,	together	with	recent	28	
publications	on	this	topic	(4,	18),	suggest	that	out	of	target	glycaemic	levels	do	not	explain	the	29	
increased	mortality	seen	in	those	with	T2D	and	multimorbidity.	Future	studies	should	try	to	identify	30	
which	factors,	other	than	glycaemic	measures,	contribute	to	the	increased	mortality	in	those	with	31	
T2D	and	multimorbidity.	32	
33	
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